validating their findings using an independent set of GBM expression profiles as well as glioblastoma xenograft models. On the basis of these results, the researchers propose a molecular ...

Despite the progress in our understanding of the process of angiogenesis and the potential of targeting these processes for the treatment of GBM, many challenges remain. Considerations regarding ...

HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain ...

On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc.

Maxim initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $3 price target The company’s lead asset is paxalisib, a potent, ...

Symphony Robotics said its goal is to reduce incision and craniotomy size to less than 4mm with its technology.

USC has received a $6m grant from the California Institute for Regenerative Medicine (CIRM) to advance a new gene therapy for ...

Expert Rev Anticancer Ther. 2012;12(5):643-654. In a Phase II study of enzastaurin in heavily pretreated patients with recurrent GBM, an objective radiographic response rate of 26% was shown at ...